Undertaking a literature review revealed that when evaluating the effectiveness of the drug treatments for dementia few studies purposefully explore the views of users and carers. Their views are mainly derived from secondary analysis of conventional scientific evidence. Where the views of users and carers were explored it was discovered that they evaluate the effectiveness of the drug treatments in terms of quality of life. On its own, the conventional scientific approach of using outcome measures to evaluate the effectiveness of drugs is not sufficiently relevant or meaningful to users and carers. Findings from a study exploring the views of users and carers also demonstrate that professionals are willing to utilize the users’ and carers’ evaluations of the drug treatments for dementia. We suggest that reliable and valid measures are developed which explicitly explore the views of users and carers. This will go towards ensuring clinical trials are relevant and meaningful to the users and carers and not to professionals alone.
Get full access to this article
View all access options for this article.
References
1.
Adams, T., & Page, S. (2000). New pharmacological treatments for Alzheimer’s disease: Implications for dementia care nursing . Journal of Advanced Nursing, 31(5), 1183-1188 .
2.
Allen, N.H.P., Gordon, S., Hope, T., & Burns, A. (1996). Manchester and Oxford Universities Scale for the Psychopathological Assessment of Dementia (MOUSEPAD) . British Journal of Psychiatry, 169(3), 293-307 .
3.
Alzheimer’s Society (2000). Appraisal of the drugs for Alzheimer’s disease: Submission to NICE: Clinical and cost effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease. London: Alzheimer’s Society .
4.
Aquilina, C., Bullock, R., Jones, R., & O’Brien, J. (2003). Interim guidance on the use of memantine (Exiba®) for Alzheimer’s disease. London: Faculty for the Psychiatry of Old Age, Royal College of Psychiatrists . Retrieved May 2003 from http://www.rcpsych.ac.uk/college/faculty/oafaculty/fmsV5b.pdf
5.
Areosa, S.A., & Sherriff, F. (2003). Memantine for dementia (Issue 2). Oxford: The Cochrane Library .
6.
Bayer, A. (1994). Carers have different priorities . Journal of Dementia Care, 2(1), 14-15 .
7.
Bayer, T. (1999). Commentary: Another piece of the Alzheimer’s jigsaw . British Medical Journal, 318(7184), 639 .
8.
Birks, J.S., & Melzer, D. (1999). Donepezil for mild and moderate Alzheimer’s disease (Issue 3). Oxford: The Cochrane Library .
9.
Birks, J.S., Iakovidou, V., & Tsolaki, M. (1999). Rivastigmine for Alzheimer’s disease (Issue 3). Oxford: The Cochrane Library .
10.
Bowling, A., Banister, D., Sutton, S., Evans, O., & Windsor, J. (2002). A multidimensional model of the quality of life in older age . Aging and Mental Health, 6(4), 355-371 .
11.
Burns, A. (1999). The clinical experience in treatment of Alzheimer’s disease . Paper presented at Optimal Management of Alzheimer’s Disease symposium. London: Royal College of Physicians.
12.
Burns, A., Lawlor, B., & Craig, S. (1999). Assessment scales in old age psychiatry. London: Martin Dunitz .
13.
Cheston, R., Bender, M., & Byatt, S. (2000). Involving people who have dementia in the evaluation of services: A review . Journal of Mental Health, 9(5), 471-479 .
14.
Concato, J., Shah, N., & Horwitz, R. (2000). Randomised, controlled trials, observational studies, and the hierarchy of research designs . New England Journal of Medicine, 342(25), 1887-1892 .
15.
Cottrell, V., & Schultz, R. (1993). The perspective of the patient with Alzheimer’s disease: A neglected dimension of dementia research . Gerontologist, 33(2), 205-211 .
16.
DeJong, R., Osterlund, O.W., & Roy, G.W. (1989). Measurement of quality of life changes in patients with Alzheimer’s disease . Clinical Therapeutics, 11(4), 545-554 .
Downs, M. (1997). The emergence of the person in dementia research . Ageing and Society, 17(5), 597-607 .
19.
European Agency for the Evaluation of Medicinal Products (1997). Notes for guidance on medicinal products in the symptomatic treatment of AD. London: Committee for Proprietary Medicinal Products Working Party .
20.
Farquhar, M. (1995). Elderly people’s definitions of quality of life . Social Science and Medicine, 41(10), 1439-1446 .
21.
Fitzpatrick, R., Davey, C., Buxton, M.J., & Jones, D.R. (1998). Evaluating patient-based outcomes for use in clinical trials (Vol. 2, No. 14). London: NHS Research & Development Health Technology Assessment Programme .
22.
Fountain, J., & Griffiths, P. (1999). Synthesis of qualitative research on drug use in the European Union: Report on an EMCDDA project. European Monitoring Centre for Drugs and Drug Addiction . European Addiction Research, 5(1), 4-20 .
23.
Gillies, B. (1997). The experience of dementia . Journal of Dementia Care, 5(6), 26 .
24.
Jones, R. (1997). Donepezil hydrochloride: A turning point for Alzheimer’s . Progress in Neurology and Psychiatry, 1(5), 36-39 .
25.
Jones, R. (2000). Drug treatments for dementia. Oxford: Blackwell Scientific Books .
26.
Keady, J. (1996). The experience of dementia: A review of the literature and implications for nursing practice . Journal of Clinical Nursing, 5(5), 275-288 .
27.
Keady, J., Nolan, M., & Gilliard, J. (1995). Listen to the voices of experience . Journal of Dementia Care, 3(3), 15-17 .
28.
McKeith, I. (1998). Why clinical trial design is so important in elderly patients with dementia . GM Clinical Advances in Drug Development Alzheimer’s Disease Trial Design, 1(1), 1-2 .
29.
National Institute for Clinical Excellence (2001). Clinical and cost effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease. London: NHS Research and Development Health Technologies Assessment Programme .
30.
NHS Centre for Reviews and Dissemination (2001). Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews. (CRD Report 4, 2nd edition) York: NHS Centre for Reviews and Dissemination .
31.
Post, S.G. (1998). The fear of forgetfulness: A grassroots approach to an ethics of Alzheimer’s disease . The Journal of Clinical Ethics, 9(1), 71-80 .
32.
Post, S.G., & Whitehouse, P.J. (1998). Emerging anti-dementia drugs: A preliminary ethical view . Journal of the American Geriatrics Society, 46(6), 784-787 .
33.
Pritchard, E., & Dewing, J. (1999a). A Multi-method evaluation of a service for people with dementia (RCN Institute Report No. 19). Oxford: Royal College of Nursing Institute .
34.
Pritchard, E., & Dewing, J. (1999b). The experiences of people with dementia and their carers of memory clinics. Unpublished report. London: Royal College of Nursing .
35.
Qizilbash, N., & Schneider, L.S. (2002). Summary, practical recommendations and opinions on therapies for cognitive symptoms and prognosis medication. In N. Qizilbash, L.S. Schneider, H. Chui, P. Tariot, H. Brodaty, J. Kaye, et al. (Eds.), Evidence-based dementia practice. (pp. 560-581). Oxford: Blackwell Publishing .
36.
Ray, L. (1999). Evidence and outcomes: Agendas, presuppositions and power . Journal of Advanced Nursing, 30(5), 1017-1026 .
37.
Reisberg, B., Schneider, L., Doody, R., Anand, R., Feldman, H., Haraguchi, et al. (1997). Clinical global measures of dementia. Position paper from the International Working Group on Harmonisation of Dementia Drug Guidelines . Alzheimer’s Disease Association Disorder, 11, Supplement 3, 8-18 .
38.
Rosen, W.G., Mohs, R.C., & Davis, K.L. (1984). A new rating scale for Alzheimer’s disease . American Journal of Psychiatry, 141(11), 1356-1364 .
39.
Royal College of Nursing (2000a). Submission to NICE: Clinical and cost effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease. London: RCN Institute .
40.
Royal College of Nursing (2000b). Survey of users’ and carers’ views and experiences of the drugs for dementia. London: RCN Institute .
41.
Selai, C., & Trimble, M. (1998). Assessing quality of life in dementia: A review . Aging and Mental Health3(2), 101-111 .
42.
Stalker, K., Gilliard, J., & Downs, M.G. (1999). Eliciting user perspectives on what works . International Journal of Geriatric Psychiatry, 14(2), 120-134 .
43.
Traynor, V., & Dewing, J. (2002). Identifying user-and carer-defined outcomes that can be used to evaluate the effectiveness of drugs for dementia: Final report presented to the Alzheimer’s Society Quality Research in Dementia Programme. London: RCN Institute .
44.
Vaughan, F., Jones, R., & Cunliffe, L. (1999). Great expectations? How carers view Aricept . Journal of Dementia Care, 7(3), 18-19 .
45.
Wilkinson, H. (Ed.). (2001). The perspectives of people with dementia: Research methods and motivations. London: Jessica Kingsley .
46.
Winblad, B., Brodaty, H., Gauthier, S., Morris, J., Orgogozo, J.M., Rockwood, et al. (2001). Pharmacotherapy of Alzheimer’s disease: Is there a need to redefine treatment success? International Journal of Geriatric Psychiatry, 16(7), 653-666 .
47.
Woods, B. (1997). Talking point: Kitwood’s ‘The experience of dementia’ . Aging and Mental Health, 1(1), 11-12 .
